Lunch Wrap: ASX seesaws into a slippery dip as markets await tariff pause deadline
Gold stocks dragging, down more than 2pc
ASX All Tech adds 0.24pc
ASX seesaws wildly ahead of tariff pause deadline
The ASX wasn't quite sure which way to go earlier this morning, but as of about 1pm AEST it seems to have made up its mind, dipping by about 0.36% at the time of publishing.
Jumping 10 points in the first five minutes, the ASX 200 dropped about the same before spiking back up again an hour later.
It's been a choppy affair ever since, but at least the utilities sector is doing its best to stem too much blood.
Looking at our large caps, market favourites Commonwealth Bank (ASX:CBA) and Northern Star Resources (ASX:NST) are trending lower, down 0.12% and 6.6% each.
NST failed to meet its revised production guidance range for the Kalgoorlie production centre, offloading 842k ounces compared to guidance of 850-860k.
The company managed to scrape just over the line for its total gold production guidance numbers, producing 1.643m ounces compared to estimates of 1.63-1.66, but the market was overall displeased with the update.
Healthcare giant CSL (ASX:CSL) is moving in the opposite direction, adding 1.94% alongside a 1.85% jump for James Hardie Industries (ASX:JHX).
Origin Energy (ASX:ORG) has also jumped more than 6% intraday, leading the greater utilities sector higher.
12 countries to receive 'take it or leave it' offers
Twelve countries currently negotiating trade deals with the US Trump administration will soon receive letters offering a final deal from the White House.
A pause on tariffs set to be imposed on the majority of US trading partners will expire on July 9, with most tariffs going into effect by August 1.
"I signed some letters and they'll go out on Monday, probably twelve," Trump said, when asked about the trade negotiations. "Different amounts of money, different amounts of tariffs."
While the Trump administration was initially very optimistic about establishing concrete trade deals with its major partners, the prez has since changed his tune, stating it was easier to send a letter.
That tracks – most major trade deals take years to negotiate, so it was always going to be a tall order to come to dozens of agreements in a matter of months.
Hotly anticipated deals with India and the EU appear to have fallen through at the last minute, leaving the door open for some big market upsets when the new tariffs finally come into effect.
On Friday, Trump added more fuel to that fire, stating tariffs could range up to 70% compared to the 10% to 50% threatened in April.
That said, investors aren't running for the hills as they were on Liberation Day.
"The markets are discounting a return to tariff levels of 35%, 40% or higher, and anticipating an across-the-board level of 10% or so,' Boston-based Twinfocus chief investment officer John Pantekidis told Reuters.
ASX SMALL CAP WINNERS
Here are the best performing ASX small cap stocks for July 7 :
Security Description Last % Volume MktCap
VN8 Vonex Limited. 0.036 100% 2156808 $13,546,863
BMM Bayanminingandmin 0.06 71% 21465707 $3,603,439
EEL Enrg Elements Ltd 0.0015 50% 546851 $3,253,779
BPM BPM Minerals 0.043 48% 9538695 $2,531,709
ZMM Zimi Ltd 0.011 38% 495333 $3,420,351
GTR Gti Energy Ltd 0.004 33% 13565308 $8,996,849
FRB Firebird Metals 0.098 27% 1505249 $10,961,828
NWM Norwest Minerals 0.014 27% 4401658 $10,651,944
KPO Kalina Power Limited 0.0075 25% 2850600 $17,597,974
BIT Biotron Limited 0.0025 25% 1617648 $2,654,492
BUY Bounty Oil & Gas NL 0.0025 25% 297011 $3,122,944
MMR Mec Resources 0.005 25% 8400000 $7,399,063
SKK Stakk Limited 0.005 25% 102300 $8,300,319
SRZ Stellar Resources 0.02 25% 15750554 $33,276,009
TMK TMK Energy Limited 0.0025 25% 501642 $20,444,766
SCP Scalare Partners 0.13 24% 2500 $4,392,677
NH3 Nh3Cleanenergyltd 0.05 22% 3120545 $26,093,310
ALY Alchemy Resource Ltd 0.006 20% 45000 $5,890,381
WSR Westar Resources 0.006 20% 840301 $1,993,624
CMO Cosmometalslimited 0.02 18% 878586 $5,476,306
DRE Dreadnought Resources Ltd 0.0105 17% 4930863 $45,715,500
AON Apollo Minerals Ltd 0.007 17% 413000 $5,570,741
AS2 Askarimetalslimited 0.007 17% 1859773 $2,425,024
LML Lincoln Minerals 0.007 17% 1550000 $12,615,418
RRR Revolverresources 0.036 16% 114474 $8,564,502
In the news…
Bayan Mining and Minerals (ASX:BMM) has staked 72 lode claims in the Mojave Desert of California in a bid to form the Desert Star rare earth project.
It's a Tier 1 area for rare earth mineralisation, just 4.5km from the Mountain Pass REE Mine (supplied 15.8% of global rare earth production in 2020) and 4.7km from Dateline Resources' (ASX:DTR) Colosseum project, which has shown similar radio metric signatures for REE mineralisation to Mountain Pass.
BMM will begin with a desktop review, field recon and rock chip sampling to drum up some early drilling targets.
Back on Australian soil, BPM Minerals (ASX:BPM) is preparing to begin drilling at its newly acquired Forelands gold project in the Yilgarn Craton–Albany Fraser Orogen margin of WA.
The project has already produced bonanza-grade hits up to 3m at 65.8 g/t gold from 25m of depth in drilling, and BPM reckons Foreland presents a near-term resource conversion opportunity.
Tenement acquisition is a bit of a theme today – Westar Resources (ASX:WSR) is also moving higher after staking a new copper tenement application in the under-explored Birrindudu Basin of Northern Territory.
The Northern Territory Geological Survey and CSIRO both found evidence of sedimentary copper deposits in a review of drill core from Birrindudu, highlighting the area as a potential frontier district for copper mineralisation.
Finally, Dreadnought Resources (ASX:DRE) is launching a test work sampling program at the Mangaroon critical metal project after fielding growing commercial interest in the rare earth and critical mineral potential of the Gillford Creek prospect.
Gillford Creek is prospective for a suite of rare earths as well as niobium, scandium, titanium, phosphorus and zirconium.
DRE management stresses that this sampling program won't distract from its 'More gold, Faster' strategy, but will advance its critical metal commercialisation ambitions.
ASX SMALL CAP LAGGARDS
Here are the worst performing ASX small cap stocks for July 7 :
Code Name Price % Change Volume Market Cap
GMN Gold Mountain Ltd 0.002 -33% 7556216 $16,859,278
FAU First Au Ltd 0.003 -25% 1009478 $8,305,165
EXT Excite Technology 0.008 -20% 1136999 $20,726,419
GGE Grand Gulf Energy 0.002 -20% 750000 $7,051,062
HTG Harvest Tech Grp Ltd 0.015 -17% 773452 $16,362,330
PV1 Provaris Energy Ltd 0.015 -17% 613604 $12,564,023
ALM Alma Metals Ltd 0.005 -17% 1224333 $11,104,423
ARV Artemis Resources 0.005 -17% 156112 $15,214,033
MRD Mount Ridley Mines 0.0025 -17% 751500 $2,335,467
NES Nelson Resources. 0.0025 -17% 31999 $6,515,783
AVM Advance Metals Ltd 0.041 -16% 6485856 $12,986,707
AGY Argosy Minerals Ltd 0.029 -15% 13769095 $49,501,312
AKN Auking Mining Ltd 0.006 -14% 2943588 $4,023,451
AYT Austin Metals Ltd 0.003 -14% 104766 $5,544,670
LCL LCL Resources Ltd 0.006 -14% 95362 $8,394,800
SPX Spenda Limited 0.006 -14% 750000 $32,306,508
SFM Santa Fe Minerals 0.125 -14% 40492 $10,558,724
SVG Savannah Goldfields 0.02 -13% 630461 $26,256,272
AJX Alexium Int Group 0.007 -13% 39265 $12,691,429
AM5 Antares Metals 0.007 -13% 2163706 $4,118,823
ATS Australis Oil & Gas 0.007 -13% 20000 $10,544,500
GSM Golden State Mining 0.007 -13% 2000000 $2,234,965
RGL Riversgold 0.0035 -13% 875981 $6,734,850
BRU Buru Energy 0.023 -12% 1504129 $20,264,650
SPQ Superior Resources 0.004 -11% 490000 $10,669,422
IN CASE YOU MISSED IT
Break it Down: MTM Critical Metals (ASX:MTM) is adding national security expert Gregory L. Bowman to the advisory board of US subsidiary Flash Metals USA.
Indiana Resources (ASX:IDA) has leveraged results from geochemical sampling near the Minos project to identify new gold targets.
Australia has a new globally focused deep tech company in MagnaTerra Technologies following the merger of mining innovator NextOre and explosives detection startup MRead.
As the US starts to ramp up domestic antimony support, Nova Minerals' (ASX:NVA) Estelle Project in Alaska is shaping up as a strategic solution.
StockTake: Anson Resources (ASX:ASN) has boosted its exploration prospects at the Green River lithium project in Utah.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
35 minutes ago
- News.com.au
Childcare to join $50m housing project linked to James Packer
A $50m affordable housing development linked to Australian billionaire businessman James Packer has put a call out for childcare operators to join a Geelong project. The planned childcare centre in the northern Geelong suburb of Corio is expected to attract significant interest from childcare operators looking to get a foothold in one of Australia's fastest growing regional cities. The centre is positioned in the heart of the Edenville residential estate being developed by Sivasli Group and will be located at 26-34 Sharland Rd which is at the entrance to the estate. Corio is expected to see a significant ramp-up in residential development. Global second-hand fashion fave eyes big entry to Geelong Melbourne developer Deniz Sivasli's Edenville group is behind the project, backed by a consortium that includes former casino mogul James Packer and investment guru Joe Gersh. Sivasli Group is also planning a 282-home residential estate on the former Flinders Peak Secondary College site in Hendy St, while Cedar Woods Properties has a 400-lot estate on the drawing board after a $35m purchase in January of an 18.6ha Plantation Rd property. The childcare development is designed by Architecton and will accommodate 124 childcare places and feature a bespoke fit-out for the incoming early learning provider across 1771sq m of building area. CBRE's Australian Healthcare and Social Infrastructure team of Sandro Peluso, Jimmy Tat and Marcello Caspani-Muto are managing the expressions of interest leasing campaign. Mr Tat said childcare centres located within residential estates tend to have outstanding occupancy rates because of increased visibility and accessibility for families. 'What truly sets Corio apart is the absence of other childcare development applications within the catchment area, making it a unique and highly attractive option for operators,' Mr Tat said. 'With over 1100 children expected to be born and move into the area over the next five years, we anticipate the demand-to-supply ratio will reach 4.3:1 – a level that is widely considered very favourable for operators.' Mr Peluso said opportunities to develop childcare centres within residential estates were rare. 'Given the highly favourable demographics and strong demand in Corio, the vendor has decided to pursue a childcare development,' Mr Peluso said. 'We expect significant interest from established local childcare providers as well as new entrants looking to break into the suburb, given the robust demand and limited competition in the area.' The Edenville estate, which will deliver 107 new homes on the site of the former Rosewall Primary School, had a difficult journey to approval at Victoria's planning umpire with Geelong's council labelling it a 'significant overdevelopment'. The expressions of interest lease campaign will close late July.
News.com.au
35 minutes ago
- News.com.au
Brickie's slick Herne Hill renovation doubles home's value in four years
A premium renovation that almost doubled the value of an original Herne Hill home has scored the suburb's most expensive sale of the year. Buyers from Newtown paid $1.4m for the transformed four-bedroom house at 5 Knight Ave. The quality of its contemporary rear extension and refit added $662,0000 to the value of the 714sq m property in four years. Geelong Real Estate Co. listing agent Ricky Forte said the front bedroom was the only thing he recognised from when he last sold the retro solid brick home for $738,000 in 2021. An open-plan living zone featuring high raked ceilings, timber floors and a sleek kitchen is the centrepiece of the redesign. 'They had done a really comprehensive, beautiful renovation,' Mr Forte said 'All the people that went through it were from Newtown, Geelong West, Manifold Heights … predominantly, as always, it was the Geelong people that were happy to fight and stretch.' He said three of the four parties that made offers on the house were considering renovating their existing homes but had been put off by construction costs that could amount to $800,000 for something similar. The buyers paid $50,000 above the top asking price to secure the property. 'I felt like nobody wanted to renovate and if you can get one that everything's been done then you just sign on the dotted line as opposed to 18 months of hell,' Mr Forte said. The vendors called on their family's construction experience to pull off the renovation – one is a bricklayer while the other's father is a builder. Recycled brickwork features in a new covered entertainment area overlooking the home's landscaped back garden. The renovation also replaced the dated 1970s brown kitchen, added a fourth bedroom and a stylish ensuite bathroom. The sale is the third million-dollar result in the street, just one block away from the Newtown border. Mr Forte said the same house in the 3220 postcode would set you back to close to $2m, which made the sister suburb an attractive value proposition. 'I think it has given a lot of people confidence that you could do a big renovation in Herne Hill and get your money back,' he said. He said another buyer who recently paid $705,000 for an older house at 18 Ashbourne St, Herne Hill, was among those who inspected the Knight Ave property for inspiration. 'He's pulling his apart and is going to build it to the Knight Ave level and now that's given him the confidence that renovating at that level that the money is there,' he said.
News.com.au
35 minutes ago
- News.com.au
ASX biotechs join global race for cell therapy breakthroughs
ASX biotechs target global cell therapy market, projected to reach ~US$48bn by 2034 Arovella the only ASX-listed biotech delving into CAR iNKT therapies and one of few globally Chimeric aims to 'break new ground' in treatment of solid tumours with CAR-T and NK cell assets Cell therapies represent a promising frontier in modern medicine, offering potential to treat, and in some cases cure diseases previously considered untreatable. By using living cells, either from the patient (autologous) or a donor (allogeneic), cell therapies aim to repair, replace, or enhance biological functions within the body. Originally pioneered for blood cancers through technologies like chimeric antigen receptor (CAR) T-cell therapies, the field is rapidly expanding into solid tumours, autoimmune conditions, and neurological diseases. Australia has close ties to CAR T-cell therapy development. Melbourne-based Cell Therapies Pty Ltd, the country's largest Therapeutic Goods Administration (TGA) licensed cell and gene therapy manufacturer, was the commercial production partner for Novartis's Kymriah – the first CAR T-cell therapy approved by the US Food and Drug Administration (FDA) in 2017. While the science remains complex, advances in manufacturing, engineering, and clinical design are making next-generation cell therapies more accessible and scalable, positioning them as a key pillar of future healthcare. Several ASX biotechs are positioning themselves at the forefront of cell therapies to capture a share of the global market, which accounted for ~US$6.04 billion in 2024 and is anticipated to close in on US$48bn by 2034, growing at a CAGR of almost 23%. In particular focus here is the treatment of solid tumours, which account for 90% of all cancers but have so far proven difficult to treat with cell therapies. Arovella in rare biotech club targeting CAR-iNKT therapies Arovella Therapeutics (ASX:ALA) is the only ASX-listed biotech delving into CAR Invariant Natural Killer T-cells (iNKT) therapies, and one of only a few globally. CEO Dr Michael Baker told Stockhead iNKT cells were distinct from the more familiar natural killer, or NK cells, which along with T-cells had limitations. T-cells can't be used off-the-shelf unless they are genetically engineered. While NK cells can quickly eliminate abnormal cells such as tumour cells, iNKT cells go further. Not only do they kill like T and NK cells, but they also trigger a longer-lasting response by activating other key parts of the immune system. Because iNKT cells recognise foreign threats differently – unlike classic CAR-T cells – it has been shown in clinical trials that iNKT cells do not cause complications like graft-versus-host disease (GvHD) when administered from a healthy donor to a patient. The FDA has approved seven CAR-T therapies to date, all for blood cancers, but no iNKT treatments. While over 120 global trials are investigating CAR-NK therapies for blood and solid tumours, CAR iNKT research remains limited. Baker said most cell therapies use the patient's own cells (autologous), but this was costly, slow, and relies on compromised cells. Arovella is taking an allogeneic approach, using healthy donor cells to create off-the-shelf, frozen doses shipped to clinics as needed in a 'ready-to-use' model. Its lead therapeutic ALA-101 combines iNKT cells with a CAR that targets CD19, a protein commonly found on B-cell blood cancers like lymphoma and leukaemia. One of Arovella's next key milestones is to apply to the FDA for its first-in-human trial, enrolling non-Hodgkin's lymphoma and leukaemia patients. The company's other key goal is also tackling solid tumours. "The first approved blood cancer targeting CAR-T products have demonstrated just how important cell therapies will be for cancer treatment," Baker said. "We look forward to using our CAR-iNKT cell platform to expand upon that work and aim to create products capable of increasing access and reducing costs. "There is a lot of great science that will continue to advance the off-the-shelf cell therapy sector. "That is why we continue to scour the globe for new IP to build into our CAR-iNKT platform, to either strengthen our CAR-iNKT cells or to broaden the cancer types that we can target.' Imugene also aims to crack solid tumours Imugene (ASX:IMU) is developing cell-based immunotherapies, including allogeneic CAR T-cell therapies, oncolytic viruses and B-cell vaccines, to address both blood cancers and solid tumours. The company's lead cell therapy candidate azercabtagene zapreleucel (azer-cel) is an off-the-shelf CAR T-cell therapy targeting CD19, a protein commonly expressed on malignant B-cells. There are no allogeneic (off the shelf) CAR T therapies approved to date. Azer-cel is currently undergoing clinical trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a hard-to-treat form of non-Hodgkin's lymphoma. In early-phase studies, azer-cel has demonstrated promising results, including high complete response rates and durable remissions in patients who have previously relapsed after autologous CAR T-cell therapies. "We are very pleased with the continued positive data coming from the azer-cel trial, which further reinforces its potential as a treatment for lymphoma patients who have failed on several previous therapies including auto CAR T," CEO and managing director Leslie Chong told Stockhead. Imugene's next-generation cell therapy platform OnCARlytics is designed to help overcome one of the biggest challenges in cancer treatment, making solid tumours visible to the immune system. The approach combines Imugene's proprietary CF33 oncolytic virus, which selectively infects and destroys cancer cells, with CD19-targeting CAR T-cells. The CF33 infects tumour cells and forces them to express CD19, a marker typically found on blood cancer cells but absent on solid tumours. By introducing CD19 into the tumour environment, the therapy effectively tags the cancer, allowing CD19-specific CAR T-cells to recognise and attack the tumour. Imugene's pipeline also includes multiple immunotherapy B-cell vaccine candidates, which involve inducing the body to produce polyclonal antibodies against specific tumour-associated antigens. The company's PD1-Vaxx is designed to generate antibodies that block the PD-1 receptor, potentially mimicking the effects of checkpoint inhibitors such as pembrolizumab (Keytruda). The company recently announced the first patient had been dosed in Australia as part of an investigator-sponsored Phase II Neo-POLEM clinical trial, which is evaluating PD1-Vaxx's potential to improve treatment outcomes for patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-high) colorectal cancer. This aggressive cancer subtype accounts for ~15% of all colorectal cancer cases. Chimeric advances cell therapy assets in solid tumours Chimeric Therapeutics (ASX:CHM) has three CAR T and NK cell assets in clinical trials. It has an ongoing phase 1/2 clinical trial for its novel CHM CDH17 CAR T-cell therapy targeting advanced colorectal cancer and Neuroendocrine tumours of the midgut. Their second program CHM CLTX CAR T is in a phase 1B clinical trial in recurrent/progressive glioblastoma, a form of brain cancer. CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial, demonstrated safety and efficacy in blood cancers and solid tumours. Two additional Phase 1B clinical trials investigating CHM CORE-NK in combination regimens have been initiated in Acute Myeloid Leukemia (AML). "We're excited to be actively advancing in the clinic and pushing through dose levels as we break new ground in the solid tumour CAR T-cell therapy space," CEO Dr Rebecca McQualter told Stockhead. Prescient advancing cell therapy platforms While predominately focused on PTX-100, its first-in-class compound with the ability to block an important cancer growth enzyme geranylgeranyl transferase-1 (GGT-1), Prescient Therapeutics (ASX:PTX) is also advancing its proprietary OmniCAR and CellPryme platforms. OmniCar has potential to allow CAR T therapy cells to be more targeted, safer, more effective, cost-effective and of longer duration. CellPryme is a complementary application to OmniCar split into two components. CellPryme-M produces superior cells that are more potent and last longer, aiming to double tumour control. Meanwhile, CellPryme-A acts as an adjuvant therapy, increasing the expansion of CAR T-cells and enhancing their ability to penetrate the tumour. AdAlta adopts East to West cellular immunotherapy strategy AdAlta (ASX:1AD) and venture capital firm SYNthesis BioVentures Fund (SYNBV) launched AdCella in 2024 to adopt an East to West strategy and bring cutting-edge cellular immunotherapies from Asia, particularly China, into Western markets. SYNBV was co-founded by Professor Andrew Wilks, who alongside Amplia (ASX:ATX) CEO Dr Chris Burns received the 2024 Prime Minister's Prize for Innovation for co-inventing momelotinib, an FDA-approved treatment for myelofibrosis. The strategy leverages AdAlta managing director and CEO Dr Tim Oldham's deep expertise in cellular immunotherapies and extensive operational experience in Asia to identify and advance promising Asian cellular therapies that can be transitioned into regulated western markets. Oldham was previously CEO of Cell Therapies and said he'd been fortunate to witness firsthand the rapid evolution of China's biotech sector and remarkable progress in cellular immunotherapies for cancer treatment over the past 15 years. The East to West cellular immunotherapy strategy for cancer is now a core growth priority for AdAlta and a key driver of future pipeline growth and value creation.
